BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia


3/5/2013 10:27:53 AM

CAMBRIDGE, Mass., March 5, 2013 /PRNewswire/ -- Tarix Pharmaceuticals, a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions, today announced it has uncovered a new role for its therapeutic peptides in stimulating revascularization following ischemia.

In models of ischemic stroke and peripheral vascular disease, treatment with either the Company's natural peptide, TXA127, or its cyclic analog, PanCyte, resulted in increased blood flow and histologic evidence of vasculogenesis (new blood vessel formation).

Rick Franklin, CEO of Tarix Pharmaceuticals, stated, "We explored the therapeutic value of our peptides following ischemia, due to their stimulatory effect on endothelial progenitor cells, which are increased naturally during ischemia and play an important role in vascular regeneration. We were very pleased, and somewhat surprised, at the efficacy seen in these models in which we saw a return to near-normal blood flow that correlated with histologic evidence of new vessel formation. In addition, in multiple models of ischemic stroke recovery, there was significant improvement in a variety of clinically relevant neurologic measurements."

Franklin continued, "Given this compelling data, we are now planning to initiate clinical trials in ischemic stroke and peripheral vascular disease in 2013."

The transient middle cerebral artery occlusion stroke model involved fifteen animals per treatment group, and was randomized and blinded. There were significant improvements in neurologic score, forelimb placement, stepping test and body swing test, all of which are standard measurements of functional response in stroke. Treatment was begun twenty-four hours after the stroke, and positive results were detectable within two weeks, and improvement continued throughout the seven-week study. In addition, there was a substantial increase in cerebral blood flow and histologic evidence of new blood vessel formation.

Separately, in a mouse model of unilateral hindlimb ischemia, ischemic recovery was compared between TXA127 or PanCyte treatment versus control animals. Blood flow in treated animals improved significantly faster toward normal, with percent blood flow more than double that of control animals by day 49 (~85% vs ~40%). Histologic examination again showed a significant increase in the number of functional blood vessels amongst treated animals compared to controls.

About Tarix Pharmaceuticals
Tarix Pharmaceuticals is a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions. Tarix' proprietary technology platform consists of TXA127, a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7), and PanCyte, a cyclic analogue of TXA127 with an extended half-life. TXA127 and PanCyte have shown striking effects in models of ischemic stroke and peripheral vascular disease through improvement in endothelial progenitor cell number and function. The peptides have also been effective in models of diabetes. Tarix intends to initiate clinical trials in these indications during 2013, adding to its clinical pipeline that includes multiple programs in hematopoiesis.

For Tarix Pharmaceuticals:

Media / Investor Contacts:

Rick Franklin

Jason Rando / Claire Sojda

Rick.franklin@tarixpharma.com

Tiberend Strategic Advisors, Inc.


212.827.0020


jrando@tiberend.com


csojda@tiberend.com

SOURCE Tarix Pharmaceuticals



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->